Radiosensitivity of human ovarian cancer cells is enhanced by pseudolaric acid B due to the inhibition of the Ras/Raf/ERK signaling pathway

Song,Quqing; Jiang,Sheng; Zhang,Xinxin; Pan,Chunxia; Lu,Chunhua; Peng,Jingwei; Li,Qingshui

doi:10.3892/etm.2017.5500

Radiosensitivity of human ovarian cancer cells is enhanced by pseudolaric acid B due to the inhibition of the Ras/Raf/ERK signaling pathway

Authors:
- Quqing Song
- Sheng Jiang
- Xinxin Zhang
- Chunxia Pan
- Chunhua Lu
- Jingwei Peng
- Qingshui Li
View Affiliations

Affiliations: Department of Gynecological Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China
Published online on: November 13, 2017 https://doi.org/10.3892/etm.2017.5500
Pages: 685-690
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer has the highest mortality rate among gynecological cancers; the most effective therapy for this cancer is a combination of radiation treatment and chemotherapy. However, radiation resistance is the leading factor associated with treatment failure. The present study aimed to investigate pseudolaric acid B (PAB) as a potential radiosensitizer for the treatment of ovarian cancer. The present study performed MTT and clonogenic assays, and demonstrated that PAB could induce a radiosensitizing effect on SKOV‑3 cells. An Annexin V/propidium iodide staining assay revealed that PAB exerted a radiosensitizing effect by inducing SKOV‑3 cell apoptosis. In addition, western blot analysis demonstrated that the activity of the Ras/RAF proto‑oncogene serine/threonine‑protein kinase/extracellular signal‑regulated kinase signaling pathway was reduced by combination therapy with PAB and irradiation. In conclusion, the present study establishes PAB as a radiosensitizer, and provides a rational basis for the use of PAB and irradiation as a combination therapy to treat ovarian cancer.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
2	Goff BA, Mandel L, Muntz HG and Melancon CH: Ovarian carcinoma diagnosis. Cancer. 89:2068–2075. 2000. View Article : Google Scholar : PubMed/NCBI
3	Bast RC Jr, Hennessy B and Mills GB: The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer. 9:415–428. 2009. View Article : Google Scholar : PubMed/NCBI
4	Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, et al: Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 27:1419–1425. 2009. View Article : Google Scholar : PubMed/NCBI
5	Schwarz R, Bruland O, Cassoni A, Schomberg P and Bielack S: The role of radiotherapy in oseosarcoma. Cancer Treat Res. 152:147–164. 2009. View Article : Google Scholar : PubMed/NCBI
6	Zhang YC, Jiang G, Gao H, Liu HM and Liang J: Influence of ionizing radiation on ovarian carcinoma SKOV-3 xenografts in nude mice under hypoxic conditions. Asian Pac J Cancer Prev. 15:2353–2358. 2014. View Article : Google Scholar : PubMed/NCBI
7	Di Pasqua AJ, Yuan H, Chung Y, Kim JK, Huckle JE, Li C, Sadgrove M, Tran TH, Jay M and Lu X: Neutron-activatable holmium-containing mesoporous silica nanoparticles as a potential radionuclide therapeutic agent for ovarian cancer. J Nucl Med. 54:111–116. 2013. View Article : Google Scholar : PubMed/NCBI
8	Wakeford R: The cancer epidemiology of radiation. Oncogene. 23:6404–6428. 2004. View Article : Google Scholar : PubMed/NCBI
9	Yu JH, Cui Q, Jiang YY, Yang W, Tashiro S, Onodera S, Onodera S and Ikejima T: Pseudolaric acid B induces apoptosis, senescence, and mitotic arrest in human breast cancer MCF-7. Acta Pharmacol Sin. 28:1975–1983. 2007. View Article : Google Scholar : PubMed/NCBI
10	Li E, Clark AM and Hufford CD: Antifungal evaluation of pseudolaric acid B, a major constituent of Pseudolarix kaempferi. J Nat Prod. 58:57–67. 1995. View Article : Google Scholar : PubMed/NCBI
11	Wang WC, Lu RF, Zhao SX and Gu ZP: Comparison of early pregnancy-terminating effect and toxicity between pseudolaric acids A and B. Zhongguo Yao Li Xue Bao. 9:445–448. 1988.(In Chinese). PubMed/NCBI
12	Wang WC, Lu RF, Zhao SX and Zhu YZ: Antifertility effect of pseudolaric acid B. Zhongguo Yao Li Xue Bao. 3:188–192. 1982.(In Chinese). PubMed/NCBI
13	Yu B, Yue DM, Shu LH, Li NJ and Wang JH: Pseudolaric acid B induces caspase-dependent cell death in human ovarian cancer cells. Oncol Rep. 31:849–857. 2014. View Article : Google Scholar : PubMed/NCBI
14	Morimoto H, Yonehara S and Bonavida B: Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res. 53:2591–2596. 1993.PubMed/NCBI
15	Brown JM: Tumor hypoxia in cancer therapy. Methods Enzymol. 435:297–321. 2007.PubMed/NCBI
16	Steffen AC, Gostring L, Tolmachev V, Palm S, Stenerlow B and Carlsson J: Differences in radiosensitivity between three HER2 overexpressing cell lines. Eur J Nucl Med Mol Imaging. 35:1179–1191. 2008. View Article : Google Scholar : PubMed/NCBI
17	Akbarzadeh M, Nouri M, Banekohal MV, Cheraghi O, Tajalli H, Movassaghpour A, Soltani S, Cheraghi H, Feizy N, Montazersaheb S, et al: Effects of combination of melatonin and laser irradiation on ovarian cancer cells and endothelial lineage viability. Lasers Med Sci. 31:1565–1572. 2016. View Article : Google Scholar : PubMed/NCBI
18	Pauwels B, Vermorken JB, Wouters A, Ides J, Van Laere S, Lambrechts HA J, Pattyn GG, Vermeulen K, Meijnders P and Lardon F: The role of apoptotic cell death in the radiosensitising effect of gemcitabine. Br J Cancer. 101:628–636. 2009. View Article : Google Scholar : PubMed/NCBI
19	Mose S, Class R, Weber HW, Rahn A, Brady LW and Bottcher HD: Radiation enhancement by gemcitabine-mediated cell cycle modulations. Am J Clin Oncol. 26:60–69. 2003. View Article : Google Scholar : PubMed/NCBI
20	Creane M, Seymour CB, Colucci S and Mothersill C: Radiobiological effects of docetaxel (Taxotere): A potential radiation sensitizer. Int J Radiat Biol. 75:731–737. 1999. View Article : Google Scholar : PubMed/NCBI
21	Hermann RM, Rave-Frank M and Pradier O: Combining radiation with oxaliplatin: A review of experimental results. Cancer Radiother. 12:61–67. 2008. View Article : Google Scholar : PubMed/NCBI
22	Zhang M, Boyer M, Rivory L, Hong A, Clarke S, Stevens G and Fife K: Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys. 58:353–360. 2004. View Article : Google Scholar : PubMed/NCBI
23	Maurer G, Tarkowski B and Baccarini M: Raf kinases in cancer-roles and therapeutic opportunities. Oncogene. 30:3477–3488. 2011. View Article : Google Scholar : PubMed/NCBI
24	Kurman RJ and Shih IeM: Pathogenesis of ovarian cancer: Lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 27:151–160. 2008.PubMed/NCBI
25	Yap TA, Carden CP and Kaye SB: Beyond chemotherapy: Targeted therapies in ovarian cancer. Nat Rev Cancer. 9:167–181. 2009. View Article : Google Scholar : PubMed/NCBI
26	Kasid U and Dritschilo A: RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene. 22:5876–5884. 2003. View Article : Google Scholar : PubMed/NCBI
27	Suy S, Anderson WB, Dent P, Chang E and Kasid U: Association of Grb2 with Sos and Ras with Raf-1 upon gamma irradiation of breast cancer cells. Oncogene. 15:53–61. 1997. View Article : Google Scholar : PubMed/NCBI
28	Sylvain V, Lafarge S and Bignon YJ: Molecular pathways involved in response to ionizing radiation of ID-8 mouse ovarian cancer cells expressing exogenous full-length Brca1 or truncated Brca1 mutant. Int J Oncol. 19:599–607. 2001.PubMed/NCBI
29	Kyula JN, Khan AA, Mansfield D, Karapanagiotou EM, McLaughlin M, Roulstone V, Zaidi S, Pencavel T, Touchefeu Y, Seth R, et al: Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling. Oncogene. 33:1700–1712. 2014. View Article : Google Scholar : PubMed/NCBI